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Introduction
============

Survival and life expectancy of children with congenital heart defects have dramatically increased in recent years due to advances in medical and surgical management strategies. Children with congenital heart disease (CHD) are at increased risk of neurodevelopmental deficits \[[@REF1]\], and the presence of sensorineural hearing loss (SNHL) may further lead to poor language skills acquisition and speech delays \[[@REF2]\]. The prevalence of SNHL in the general pediatric population is estimated to be 0.2% at birth to 0.35% during adolescence \[[@REF3]\]. Many studies have estimated the prevalence of SNHL in the premature neonate population and have identified several associated risk factors \[[@REF4]\]. One such study estimated the prevalence in neonates to be as high as 13.7% \[[@REF5]\]. Very few studies, however, have attempted to estimate the prevalence of SNHL in children who have undergone congenital heart surgery. Of these studies, one old study estimated the prevalence to be 16% in CHD patients \[[@REF6]\], and a recent study estimated the prevalence to be as high as 28.6% among childhood survivors after the Norwood/Sano operation only \[[@REF7]\]. Currently, no clear recommendations exist for audiology screening in patients undergoing repair or palliation of CHD. The American Heart Association recommends audiology examination if there is no audiology examination since birth and if there is any suspicion of hearing impairment after cardiac surgery \[[@REF8]\].

The first purpose of this study was to estimate the prevalence of SNHL in children who underwent congenital heart surgery in our institution and were followed up in our high-risk pediatric cardiology clinics for four years, from 2009 to 2013. The prevalence of SNHL in single-ventricle (SV) patients was also compared to that in biventricular (BiV) patients. Another objective of this study was to identify all possible risk factors associated with SNHL in palliated CHD patients to assess the need for routine hearing screening in patients with complex CHD.

Materials and methods
=====================

We performed a retrospective chart review of patients followed in our high-risk pediatric cardiology clinics from 2009 to 2013 who had routine audiology evaluations. The study design was approved by the institutional review board. Data were collected on patient demographics and preoperative variables such as prematurity and birth weight, presence of genetic syndromes, as well as surgical variables such as total cardiopulmonary bypass time, circulatory arrest time, and cross-clamp time (Table [1](#TAB1){ref-type="table"}).

###### Demographic characteristics of patients

CHD: congenital heart disease.

  ------------------------------- --------------------- ------------- ----------- -------
  Characteristic                  Hearing               Z statistic   P Value\*   
  Normal hearing (n=125)          Hearing loss (n=20)                             
  Sex                                                                             
  Male                            79 (63.2%)            15 (75%)      -1.023      0.307
  Female                          46 (36.8%)            5 (25%)                    
  Prematurity                                                                     
  No                              110 (88%)             15 (75%)      -1.560      0.119
  Yes                             15 (12%)              5 (25%)                    
  Diagnosis                                                                       
  Mild CHD                        7 (5.6%)              0             -1.089      0.276
  Moderate 2V CHD                 21 (16.8%)            0                          
  Severe 2V                       33 (26.4%)            9 (45%)                    
  Palliated 1V                    64 (51.2%)            11 (55%)                   
  Hearing loss status                                                             
  Moderate/Severe/Profound loss                         10 (45%)      -11.967     0.000
  Mild loss                                             11 (55%)                   
  Hearing aids status                                                             
  Yes                                                   4 (20%)       -11.563     0.000
  No                                                    16 (80%)                   
  \*Wilcoxon Mann-Whitney                                                         
  ------------------------------- --------------------- ------------- ----------- -------

Post-operative variables were also collected. These included lowest arterial P^H^. and PaO2, exposure to known ototoxic medications such as furosemide, hydrochlorothiazide, gentamycin, and vancomycin and their cumulative doses in mg/kg along with duration, inotropic scores in the first two postoperative days, need for extracorporeal membrane oxygenation (ECMO), and clinical seizures. Data collection was performed by a research assistant who was blinded to the hearing test results. Table [2](#TAB2){ref-type="table"} shows various diagnoses in the study patients.

###### Various diagnoses in the study patients

CoA: coenzyme A; IAA: interrupted aortic arch; AS: aortic stenosis; DILV: double inlet left ventricle; DORV: double outlet right ventricle; DTGA: d-transposition of the great arteries; HLHS: hypoplastic left heart syndrome; PA: pulmonary atresia; IVS: intact ventricular septum; VSD: ventricular septal defect; L-TGA: levo-transposition of the great arteries; TAPVR: total anomalous pulmonary venous return; ASD: atrial septal defect; MV: mitral valve.

 

 

  ------------------------------------------------------------------------------------------- --------------------
  Diagnosis                                                                                   Number of patients
  Arch anomaly (CoA, IAA)                                                                     13
  AS/sub AS                                                                                   3
  AVC/TOF                                                                                     12
  DILV                                                                                        6
  DORV                                                                                        8
  DTGA                                                                                        15
  Heterotaxy                                                                                  7
  HLHS                                                                                        44
  HRHS (PA/IVS, PA,VSD)                                                                       18
  VSD                                                                                         7
  Other (L-TGA, TAPVR, Sinus venosus ASD, Coronary anomalies, Truncus, Isolated MV disease)   12
  ------------------------------------------------------------------------------------------- --------------------

Exclusion criteria were any known genetic syndrome association with SNHL or family history of hearing loss, and any previously documented failed newborn screening. Drug dosages were calculated as cumulative doses in mg/kg based on the weight at the time of each operation. Audiology assessment was performed by an experienced pediatric audiologist using age-appropriate and standard procedures. Young children and developmentally delayed children underwent visually reinforced audiometry, while older children underwent behavioral audiological assessment using pure tone audiometry. All children with test results indicating impaired hearing underwent auditory brain stem response for confirmation. Hearing loss was classified as mild when the hearing loss range in decibels (dB) was 26-40 db. Hearing loss range in dB \> 40 dB was grouped as moderate to severe to profound loss \[[@REF9]\]. Comparisons between normal and abnormal hearing groups were done using the t test. All collected data were de-identified and stored in a password-protected computer database. All statistical tests were run using Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL).

Results
=======

A total of 172 patients were identified, 20 of whom were found to have hearing impairment ranging from mild loss to moderate to severe to profound loss in one or both ears. No patient met the exclusion criteria. The prevalence of SNHL in asymptomatic; palliated/repaired CHD patients followed in our high-risk clinics undergoing routine surveillance was 11.6% (20 with hearing impairment out of 172 patients). The prevalence of SNHL was higher in SV patients (17.2%) compared to BiV patients (14.7%), but there was no statistically significant difference (odds ratio 1.16, confidence interval: 0.45-3) (Table [3](#TAB3){ref-type="table"}). Twenty-seven out of 172 patients were eliminated from univariate analysis due to lack of records, as their surgeries were performed in a different institution. A total of 145 patients were reviewed for univariate analysis. Inotropic score in the first 24 hours of postoperative period (p= 0.05), lowest arterial PaO2 (p=0.003), the duration of furosemide drip (p=0), and bolus doses in days (p=0.03) were found to be statistically different between the two groups (Table [4](#TAB4){ref-type="table"}). However, using logistic regression, we identified no statistically significant predictors for hearing loss.

###### Prevalence of hearing loss in single-ventricle patients and biventricular patients

SV: single-ventricle; BiV: biventricular; CI: confidence interval

  -------------------------------- -------------- ---------------- ------------
                                   Hearing Loss   Normal Hearing   Prevalence
  SV Pts                           11             64               17.2%
  BiV Pts                          9              61               14.7%
  Odds Ratio 1.16; CI 0.45-3                                       
  Z statistic 0.32; p-value 0.75                                   
  -------------------------------- -------------- ---------------- ------------

###### Univariate analyses

CPB: cardiopulmonary bypass; ECMO: extracorporeal membrane oxygenation.

  ---------------------------------------------------------------------------------------- ------------------------ --------------------- --------- ---------------- ---- --------- --------- ---------------- ------------- ---------
                                                                                           Normal Hearing (N=125)   Hearing Loss (N=20)                                                                                      
                                                                                           N                        Mean                  Median    Std. Deviation   N    Mean      Median    Std. Deviation   t Statistic   p value
  Wks prematurity                                                                          13                       35.115                35.700    1.361            5    35.140    36.000    2.332            -0.028        0.978
  Birth Weight (Kg)                                                                        112                      3.123                 3.100     0.643            18   2.872     2.910     0.545            1.566         0.120
  No. Cardiac Surgeries                                                                    125                      2.272                 2.000     1.058            20   2.450     2.000     0.887            -0.810        0.425
  CPB time (min)                                                                           125                      193.168               198.000   108.228          19   189.158   171.000   90.258           0.153         0.878
  Arrest time (min)                                                                        125                      24.816                0.000     32.226           19   23.368    0.000     26.243           0.186         0.852
  Aortic CC time (min)                                                                     125                      80.024                67.000    64.365           19   80.368    84.000    80.670           -0.021        0.983
  VIS24                                                                                    125                      20.012                18.000    14.166           19   26.732    30.000    15.169           -1.909        0.058
  VIS48                                                                                    125                      15.800                16.000    12.312           19   21.342    22.000    14.953           -1.775        0.078
  Lowest Arterial Ph                                                                       120                      7.241                 7.250     0.097            19   7.196     7.220     0.095            1.867         0.064
  Lowest Arterial PO2\*                                                                    120                      37.825                30.000    20.017           19   29.421    26.000    8.681            3.109         0.003
  Number of Ventilator days                                                                124                      12.194                10.500    11.929           19   29.105    18.000    38.894           -1.882        0.076
  Cumulative Lasix drip dose (mg/kg)                                                       120                      22.390                0.650     47.550           18   26.776    17.700    32.171           0.378         0.706
  Total Lasix drip days\*                                                                  121                      54.160                4.000     107.811          18   7.167     4.500     7.950            4.710         0.000
  Cumulative Lasix Bolus dose (mg/kg)                                                      119                      93.800                62.530    101.768          18   101.139   80.650    106.782          0.283         0.777
  Total Lasix Bolus days\*                                                                 124                      11.742                8.500     11.665           18   24.967    19.500    23.719           -2.325        0.032
  Cumulative Gentamycin dose (mgkg)                                                        124                      24.887                3.500     55.672           18   57.037    17.785    84.953           -1.558        0.136
  Total Gentamycin days                                                                    124                      6.250                 0.000     24.168           18   13.167    4.000     18.875           -1.162        0.247
  Cumulative Vancomycin dose (mgkg)                                                        124                      264.223               0.000     624.629          18   394.130   28.500    677.284          -0.816        0.416
  Total Vancomycin days                                                                    124                      3.597                 0.000     6.351            19   11.842    2.000     19.909           -1.791        0.900
  Cumulative Diuril dose (mgkg)                                                            123                      59.427                8.240     241.799          18   28.444    11.400    40.366           0.541         0.589
  Total Diuril days                                                                        123                      3.577                 2.000     5.940            18   6.000     2.500     7.585            -1.557        0.122
  Total ECMO days                                                                          125                      0.280                 0.000     1.3947           19   0.421     0.000     1.835            -0.393        0.695
  \* Significant difference between groups t-test                                                                                                                                                                            
  Highlighted items with p-value less than 0.1 were included in the logistic regression.                                                                                                                                     
  ---------------------------------------------------------------------------------------- ------------------------ --------------------- --------- ---------------- ---- --------- --------- ---------------- ------------- ---------

Discussion
==========

In our high-risk cohort, we estimated the prevalence of hearing loss of 11.6%, which is higher than in the general pediatric population as well as in neonatal intensive care unit (NICU) survivors (2%-4%) \[[@REF10]\]. Limitations of the study include the small population size and the deficiency that not all patients underwent elective screening after congenital heart surgery. Only those patients followed up in high-risk pediatric cardiology clinics underwent the hearing test. Hence a true prevalence is not possible to calculate from the study. However, the study provides an estimate of prevalence which is higher than the prevalence of SNHL in the general pediatric population. This prevalence study did not examine all possible etiologies of SNHL like cytomegalovirus (CMV) infection, as no serologies were done to test for CMV infection due to this being a retrospective study. The biggest strength of this study is that the exposure to ototoxic medications was compared in the groups. The other advantage of our study is that it included all complexities of CHD, including mild CHD, moderate 2 ventricle, severe 2 ventricle, and palliated single ventricle, and could represent the estimated prevalence in repaired/palliated CHD in general.

Inner ear ischemia and hypo perfusion are the main proven physiological mechanisms for hearing loss after open heart surgery \[[@REF11]-[@REF12]\]. Hypoxia and bolus administration of furosemide have been reported to be significant risk factors for hearing loss in children after cardiopulmonary bypass surgery \[[@REF7]\]. The duration of ECMO therapy and clinical seizure activity prior to ECMO are independently associated with SNHL \[[@REF13]\].

Conclusions
===========

Our study supports the previously proven etiologies of hypoxia and longer duration of furosemide as strongly associated with SNHL. However, using logistic regression, we identified no single independent predictor as statistically significant for causing hearing loss in complex CHD. But because of the high prevalence of SNHL in this group, the results suggest the need for routine audiology screening of all patients with complex CHD, especially in patients who have undergone neonatal cardiac repair as well as palliation below one year of age, irrespective of risk factors. This screening is necessary to identify children at risk and intervene before SNHL negatively affects their neurodevelopment.
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